Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 6Genitourinary 3Tumor-Agnostic 2Other solid neoplasm 2Breast 2Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Neoplasms 2

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × fluzoparib × Tumor-Agnostic × Clear all
NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

University Hospital, Caen

Completed
2,336 enrolled
Tumor-Agnostic

Neoplasms

NCT02759666 2019-09-19

A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors

Atridia Pty Ltd.

Phase 1 Completed
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡